IL6 and Alzheimer disease: Compared with the model group, the levels of IL-1β, IL-6, TNF-ɑ, and NO in the brain of AD mice in the administration group were significantly decreased (p < 0.05, p < 0.01), suggesting that all the three key active ingredients inhibited the inflammatory response in the brains of AD mice (Figures 10B–E).